Healthcare Providers and Services
Company Overview of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Compensation as of Fiscal Year 2015.
Memorial Sloan Kettering Cancer Center Key Developments
Atara Biotherapeutics, Inc. Exercises License Agreement with Memorial Sloan Kettering Cancer Center
Jun 16 15
Atara Biotherapeutics Inc. has exercised its exclusive option with Memorial Sloan Kettering Cancer Center (MSK) to license certain clinical stage, allogeneic T-cell therapies for the treatment of cancers and persistent viral infections. In connection with the exercise of the option, the Atara license agreement with Memorial Sloan Kettering Cancer Center grants Atara exclusive worldwide rights to the following three allogeneic T-cell therapies: T-cells activated against Epstein Barr Virus, or EBV (Phase 2); T-cells activated against cytomegalovirus, or CMV (Phase 2); and T-cells activated against Wilms Tumor 1, or WT1 (Phase 1). In connection with the exercise of the option and entry into the exclusive license agreement, Memorial Sloan Kettering Cancer Center received an upfront license fee and will be eligible to receive additional payments based on the achievement of certain development, regulatory and sales-related milestones, as well as royalty payments. Atara and Memorial Sloan Kettering Cancer Center have agreed to collaborate on further research to develop additional cellular therapies, which may include T-cell therapies targeted against other antigens and/or chimeric antigen receptor-modified T-cells, known as CAR-T.
Memorial Sloan Kettering Cancer Center Presents at Barclays Select Series: PBM Drug Pricing & Formulary Management Symposium, Jun-17-2015
Jun 15 15
Memorial Sloan Kettering Cancer Center Presents at Barclays Select Series: PBM Drug Pricing & Formulary Management Symposium, Jun-17-2015. Venue: Barclays, 745 Seventh Avenue, New York City 10019, United States. Presentation Date & Speakers: Jun-17-2015, Peter Bach, Director, Center for Health Policy and Outcomes.
Peregrine Pharmaceuticals Enters into Research Collaboration with Memorial Sloan Kettering Cancer Center to Investigate Novel PS-Targeting Immunotherapy Combinations
May 29 15
Peregrine Pharmaceuticals, Inc. announced that the company has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to explore the potential of Peregrine's proprietary phosphatidylserine (PS)-targeting antibody platform. The goal of the research is to identify effective treatment combinations based on Peregrine's PS-targeting agents, including Peregrine's lead clinical agent bavituximab, with other checkpoint inhibitors or immune stimulating agents that will further guide the bavituximab clinical development program. As part of the collaboration, researchers at MSK will conduct research to further explore the combination of PS-targeting agents, including bavituximab, that block a primary immunosuppressive pathway thereby allowing anti-tumor immune responses with other immuno-stimulatory agents that enhance immune responses. Specifically, MSK researchers will examine the combination of bavituximab alongside models of checkpoint blockade that are unresponsive to inhibition or co-stimulation given the ability of bavituximab to reprogram myeloid derived suppressor cells (MDSC) and increase tumoricidal T-cells in tumors, a mechanism of action that is complementary to checkpoint blockade and T-cell activation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|